American Osteopathic Academy of Addiction Medicine - AOAAM

Home
United States
Chicago, IL
American Osteopathic Academy of Addiction Medicine - AOAAM

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from American Osteopathic Academy of Addiction Medicine - AOAAM, Addiction Resources Center, 1018 W Madison Stree, Suite 9, Chicago, IL.

American Osteopathic Academy of Addiction Medicine (AOAAM) represents osteopathic physicians involved in the treatment of alcoholism and substance use disorder.
--
https://aoaam.start.page

03/13/2026

📢 Save the Date – Complimentary Webinar

AOAAM, in partnership with the Opioid Response Network (ORN), invites healthcare professionals to the next webinar in the ORN Spring 2026 Hot Topics in Addiction Medicine Series.

🗓 May 13, 2026

⏰ 5:00 PM ET

This session will explore the emergence of medetomidine — a highly potent veterinary alpha-2 adrenergic agonist — as an adulterant in the U.S. illicit opioid supply and the implications it may have for clinical management and systems of care.

Join us as we begin to unpack the clinical effects, toxicity, and treatment considerations surrounding this emerging substance.

🔎 Stay tuned!

We’ll be sharing the speaker announcement and additional webinar details soon, including learning objectives and key takeaways.

🔗 Registration is required:

https://education.aoaam.org/products/orn-spring-2026-medetomidine-impacts-on-clinical-management-and-systems-of-care

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

03/13/2026

Now published in the Journal of Addictive Diseases:

Central sensitization in alcohol use disorder: correlates of pain, addiction and health-related quality of life

This study is the first to apply a validated surrogate measure of central sensitization in a clinical sample of individuals with AUD.

The results advance mechanistic understanding of the intersection between chronic pain and alcohol use disorder.

Read the full article:
🔗 https://doi.org/10.1080/10550887.2023.2237396

03/12/2026

🎓 Live Webinar Series – Includes CME

Join us for the 4-hour MOUD DEA Training live webinar, “Understanding Addiction Pharmacology of Medications for Opioid Use Disorders,” on:

🗓 Saturday, May 2, 2026

⏰ 8:00 AM – 12:15 PM ET

This live training will explore key topics shaping the field of addiction medicine and provide practical insights into the pharmacology and clinical use of medications for opioid use disorders (MOUD).

The session will be led by Dr. Stephen A Wyatt, DO, a Board-Certified Psychiatrist with subspecialty certification in Addiction Psychiatry. Dr. Wyatt currently serves as Psychiatry Faculty at MAHEC in Asheville, NC and is an adjunct professor at the University of North Carolina. He is a past president of AOAAM, Chair of the COPE: The Coalition on Physician Education in Substance Use Disorders, and a clinical expert for the SAMHSA-funded Provider Clinical Support System (PCSS).

💡 Continuing Medical Education (CME) Credits Available

Participants in this program may earn:

✔ Up to 4 AOA Category 1-A Credits
✔ Up to 4 AAFP Credits

Earn valuable continuing education credits while enhancing your professional knowledge in the treatment of opioid use disorder.

📚 Learning Objectives

By the conclusion of this webinar series, attendees will be able to:

• Describe the value of utilizing evidence-based treatment in identifying and caring for patients with substance use disorder
• Prescribe buprenorphine products using a safe and effective management plan
• Improve confidence and comfort in managing patients with opioid use disorder

🎯 Outcomes

At the completion of this program, healthcare providers will be better equipped to prevent, identify, and understand evidence-based treatment approaches for opioid use disorders.

⚠️ Registration is required for each live webinar individually.

If you have not registered for one of our live webinars in the past, please subscribe to AOAAM, then login and register.

🔗 Register here:

https://education.aoaam.org/Public/Catalog/Details.aspx?id=KJoPXiDn%2b0vnzXEdJKCBsA%3d%3d

🔗 Learn more about PCSS resources, trainings, and national updates:

pcssnow.org

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

03/12/2026

📢 Save the Date – Complimentary Webinar

AOAAM, in partnership with the Opioid Response Network (ORN), invites you to the first webinar in the ORN Spring 2026 Hot Topics in Addiction Medicine Series.

🗓 May 6, 2026
⏰ 5:00 PM ET

This session will explore the rapid diversification of kratom-derived products, including compounds such as 7-hydroxymitragynine, pseudoindoxyl, and related substances, and the growing impact these substances are having on clinical care and public health.

As new kratom-derived compounds continue to emerge, clinicians are increasingly encountering questions about their pharmacology, risks, and implications for the treatment of substance use disorders.

🔎 Stay tuned for upcoming posts revealing our featured speaker and additional details.

🔗 Registration is required:
https://education.aoaam.org/products/orn-spring-2026-update-on-the-diversification-of-kratom-derive…

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

03/03/2026

Now Available On-Demand!

Su***de risk is significantly elevated among individuals with opioid use disorder (OUD). In this ORN Summer 2025 session, Max Spaderna, MD examines why — including research findings, intentional opioid overdose, and the clinical challenges of identifying those at risk.

Participants will be able to:
✔ Evaluate su***de risk in individuals with OUD
✔ Explain key associated characteristics
✔ Describe the relationship between intentional overdose and su***de risk
✔ Identify challenges in assessment and prevention

CME Credits Available:
1 AOA Category 1-A Credit | 1 AMA PRA Category 1 Credit™ | 1 AAPA Category 1 CME Credit | 1 Nurses CNE Credit

Participants may earn CME/CNE credit upon completion.

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from Substance Abuse and Mental Health Services Administration

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

🔗 https://education.aoaam.org/Public/Catalog/Details.aspx?id=oED8VFlm3ky09PGEb8PhuA%3d%3d

NAV & Associates is proud to support research and initiatives that advance addiction science and promote better outcomes for patients and communities.

***dePrevention

02/27/2026

Check out this article from the Journal of Addictive Diseases (JAD):

“Inpatient initiation of long-acting injectable buprenorphine at a community hospital: A retrospective case series”

This study highlights the feasibility and safety of initiating long-acting injectable buprenorphine (LAIB) during hospitalization — even with minimal sublingual lead-in.

Key findings:
• 50% attended a follow-up appointment within 30 days (vs. 30% historical baseline)
• 87% received LAIB with fewer than seven days of sublingual buprenorphine
• No precipitated withdrawal after LAIB administration

Hospital-based LAIB may help improve post-discharge engagement in care.

Read more:
🔗 https://lnkd.in/g36uQi9a

02/13/2026

From one provider treating 20 patients to a thriving program serving 90 — this is what happens when passion meets support.

In 2020, Andrew Johnstone, APN, FNP, MSN, BC, was the only prescriber in his practice treating patients with opioid use disorder. Today, Jefferson Health has built a compassionate, evidence-based MOUD program that not only supports patients through every stage of recovery — including relapse — but is now helping other clinics do the same.

With support from Pcss-Moud Implementation, the team developed flexible clinical guidance, strengthened partnerships with behavioral health and social services, and built a culture where patients are met with encouragement, not judgment.

“If a patient relapses, that’s okay. We say, ‘I’m proud of you for coming back.’”

This is what whole-person, evidence-based care looks like.

Read the full article here: https://pcssnow.org/real-stories/new-jersey-primary-care-practice-a-model-for-treating-patients-with-oud/

02/10/2026

Addiction Is a Treatable Medical Condition

Addiction is a chronic, treatable medical condition—not a moral failing, and many people achieve meaningful, sustained recovery with appropriate care.

Decades of research show that evidence-based addiction treatment significantly reduces mortality, improves physical and mental health, and supports long-term recovery. Like other chronic diseases, outcomes improve when care is continuous, comprehensive, and medically informed.

Despite this evidence, many patients still face barriers to treatment due to systemic stigma, lack of trained providers, and limited access to education about addiction medicine. Closing these gaps is essential to improving patient outcomes and strengthening health systems.

AOAAM advances evidence-based, whole-person addiction care through education, leadership development, and interdisciplinary collaboration—empowering clinicians to treat addiction with the same rigor as any other chronic illness.

🔗 Supporting research:

https://nida.nih.gov/research-topics/addiction-science

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509636/

02/06/2026

“Addiction is a chronic disease of the brain, not a character flaw.”
— Dr. Nora D. Volkow, Director, National Institute on Drug Abuse (NIDA)

Understanding substance use disorder as a medical condition is essential to delivering effective, evidence-based care. Education helps reduce stigma, improve access to treatment, and support long-term recovery.

01/30/2026

Methadone plays a critical role in treating opioid use disorder—especially in acute care settings. Join this PCSS-MOUD clinical roundtable to learn how methadone is used in acute care, when and how to initiate treatment rapidly, and what the latest evidence shows. Earn CME credit while gaining practical, timely insights for clinical practice.

Funding for this initiative was made possible (in part) by grant nos. 1H79TI086770 and 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Register here: https://education.sudtraining.org/Public/Catalog/Details.aspx?id=9tpN9zNBYC45XVCrhJl6HQ%3D%3D

01/29/2026

Opioid overdoses continue to impact communities nationwide, and clinicians are on the front lines of prevention and treatment every day. Now more than ever, access to real-time, evidence-based support is essential.

The PCSS-MOUD Mentoring Program connects healthcare professionals with experienced mentors to strengthen confidence, clinical decision-making, and patient outcomes in opioid use disorder care. By becoming a mentor, you can help expand access to life-saving treatment, support your peers, and play a direct role in advancing evidence-based practices across the country.

Your expertise matters. Your guidance can make a difference. Join the PCSS-MOUD Mentor Network and help turn the tide on opioid overdose.

Funding for this initiative was made possible (in part) by grant nos. 1H79TI086770 and 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

01/21/2026

This is a reminder to renew your AOAAM membership if you have not yet done so. Please visit AOAAM.org and log in to your account to renew.

Members who have already renewed are encouraged to log in and verify that their account information is current.

For assistance, please contact info@aoaam.org.

Thank you,
AOAAM Staff

Address

1018 W Madison Stree, Suite 9
Chicago, IL
60607

Website

https://aoaam.start.page/, https://aoaam.org/

Alerts

Be the first to know and let us send you an email when American Osteopathic Academy of Addiction Medicine - AOAAM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to American Osteopathic Academy of Addiction Medicine - AOAAM:

Shortcuts

Want your practice to be the top-listed Clinic in Chicago?

03/13/2026

03/13/2026

03/12/2026

03/12/2026

03/03/2026

02/27/2026

02/13/2026

02/10/2026

02/06/2026

01/30/2026

01/29/2026

01/21/2026

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category